{
  "id": "promis-neurosciences-lines-up-up-to-175-m-private-placement-to-fund-alzheimer-s-trial",
  "title": "ProMIS Neurosciences lines up up to $175 M private placement to fund Alzheimer’s trial",
  "summary": "ProMIS Neurosciences Inc., a clinical-stage biotechnology company focused on antibody therapeutics for neurodegenerative diseases, announced that it has entered into a private investment in public equity (PIPE) financing agreement with institutional and accredited investors to raise up to approximately $175 million, the company said. Under the agreement, ProMIS will issue and sell a combination of […] The post ProMIS Neurosciences lines up up to $175 M private placement to fund Alzheimer’s trial appeared first on Longevity.Technology.",
  "url": "https://longevity.technology/news/promis-neurosciences-lines-up-up-to-175-m-private-placement-to-fund-alzheimers-trial/",
  "source": "Longevity.Technology",
  "author": null,
  "category": "news",
  "publishedAt": "2026-02-02T03:41:06.000Z",
  "fetchedAt": "2026-02-04T10:49:05.817Z",
  "relevanceScore": 0.5,
  "matchedKeywords": [
    "longevity",
    "alzheimer"
  ],
  "relatedProducts": [],
  "type": "web",
  "savedAt": "2026-02-04T10:49:05.861Z"
}